Day One Biopharmaceuticals Executives Sell Shares Worth $6.77 Per Share.
ByAinvest
Tuesday, Aug 19, 2025 7:43 pm ET1min read
DAWN--
Day One Biopharmaceuticals, Inc. announced that Director, Chief Executive Officer Jeremy Bender sold 16,058 shares at $6.77 per share on August 18, 2025. Gen Counsel and Secretary Adam Dubow sold 4,365 shares at the same price on the same day, while Chief Commercial Officer Lauren Merendino sold 3,766 shares and Chief Operating Officer and Chief Financial Officer Charles N. York II sold 4,106 shares, all at $6.77 per share on August 18, 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet